Belgian regulator opens insider trading probe into Belgian biotech CEO

By Marine Strauss

BRUSSELS (Reuters) – Belgium’s financial services and markets authority (FSMA) said on Wednesday it had opened an investigation into suspected insider trading against the chief executive of Mithra Pharmaceuticals (BR:).

Francois Fornieri is suspected of buying Mithra shares via a third party in order to avoid mandatory notifications to the regulator, FSMA said, adding it had been looking into the case since September.

Liege-based Mithra was not immediately available to comment, while the Liege prosecutor declined to comment on the case.

Fornieri was quoted in Belgian business daily L’Echo as saying the allegation was nonsense, asking why he would do such an elaborate move to buy 40,000 shares when he already owned almost 13 million.

Mithra develops women’s health products, focused on contraception and the menopause, and had a market capitalisation of 1.01 billion euros ($1.12 billion) at Tuesday’s close, according to Refinitiv data.

The company’s shares were down 3.5% at 24.92 euros at 1330 GMT on Wednesday.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.